Skip to main content
. 2020 Jul 28;22(5):e13377. doi: 10.1111/tid.13377

FIGURE 1.

FIGURE 1

Chest computed tomography (CT) images of a kidney transplant recipient affected by SARS‐CoV‐2 treated with tocilizumab. (A) Multiple bilateral ground‐glass opacities, prominent on the right. (B) Multiple patchy subpleural consolidations bilaterally. (C‐D) Chest CT scans of the same patient eight days after tocilizumab administration, showing an improvement of lung infiltrates